Rapamycin for treatment of epilepsy: Antiseizure, antiepileptogenic, both, or neither?

Epilepsy Currents

Volumn 11, Issue 2, 2011, Pages 66-68

  Wong, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; EPILEPSY; EPILEPTOGENESIS; MOSSY FIBER; NERVE FIBER GROWTH; NONHUMAN; NOTE; PROTEIN FUNCTION; SEIZURE; TREATMENT OUTCOME;

EID: 84858006041     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7511-11.2.66     Document Type: Note

References (14)

1. Franz DN. mTOR in tuberous sclerosis and other neurological disorders. Epilepsia 2007;48:1630-1631.
2. Wong M. Mammalian target of rapamycin (mTOR) inhibition as potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia 2010;51:27-36.
3. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008;28:5422-5432.
4. Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008;63:444-453.
5. Ehninger D, Han S, Shiyansky C, Zhou Y, Li W, Kwaitkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008;14:843-848.
6. Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C, Powell CM, Parada LF. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci 2009;29:1773-1783.
7. Ljungberg MC, Sunnen CN, Lugo JN, Anderson AE, D'Arcangelo G. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2009;2:389-398.
8. Krueger DA, Care MM, Holland K, Agricola K, Tydor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-1811.
9. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009;29:6964-6972.
10. Buckmaster PS, Ingram EA, Wen X. Inhibition of the mammaliantarget of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J Neurosci 2009;29:8259-8269.
11. Daoud D, Scheld HH, Speckmann EJ, Gorji A. Rapamycin: Brain excitability studied in vitro. Epilepsia 2007;48:834-836.
12. Ruegg S, Baybis M, Juul H, Dichter M, Crino PB. Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res 2007;77:85-92.
13. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci 2011;2337-2347.
14. Zeng LH, McDaniel SS, Rensing N, Wong M. Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR):A double-edged sword? Cell Cycle 2010;9:2281-2285.